Should I Buy SYRE Stock in 2026?
Data-driven analysis and honest assessment for Spyre Therapeutics Inc
Current Price: $73.01
Decision Score
Weak
Based on 6 fundamental factors
Score Breakdown:
P/E data not available
Declining -0%
Currently unprofitable
Financial health data limited
Negative free cash flow
No recent insider activity
Key Investment Metrics
Current Price
$73.01
P/E Ratio
N/A
Revenue Growth
N/A
Profit Margin
N/A
Market Cap
$5.9B
Dividend Yield
None
How SYRE Compares to Competitors
Understanding how SYRE stacks up against peers helps inform your investment decision.
How SYRE Compares to Peers
Upcoming Events for SYRE
+5 Reasons TO Buy SYRE
Limited data available to identify compelling buy reasons. Consider this a yellow flag.
-5 Reasons NOT to Buy SYRE
1. Negative free cash flow
high riskBurning cash creates funding risk and limits shareholder returns.
2. Minimal revenue growth
low riskGrowth of 0.0% barely keeps pace with inflation.
Who Should Buy SYRE?
Investment Profile
Risk Level
High
Recommended Holding Period
3-5 years
Best For:
Not Suitable For:
- ✗
Growth Investors
Limited 0% growth may disappoint
- ✗
Income-Focused Retirees
No dividend paid
- ✗
Risk-Averse Investors
High risk may cause uncomfortable volatility
- ✗
Large Position Traders
Lower liquidity may impact execution
Consider These Alternatives
If you're interested in SYRE, compare these Health Care peers:
Pro tip: Compare SYRE directly with competitors using our comparison tool to see which stock better fits your criteria.
Get the Full Picture
Access AI-powered insights, DCF valuations, insider trading data, and real-time analysis for SYRE
Frequently Asked Questions
What is SYRE stock price today?
SYRE (Spyre Therapeutics Inc) stock is trading at $73.01 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).
Is SYRE stock going up or down today?
SYRE stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.
Should I buy SYRE stock now?
The decision to buy SYRE depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.
Is SYRE a buy, hold, or sell right now?
Our AI-powered analysis provides buy/hold/sell recommendations for SYRE based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.
Is SYRE stock overvalued or undervalued?
Use our DCF valuation calculator to determine if SYRE is overvalued or undervalued based on fundamental analysis and future cash flow projections.
What is SYRE's P/E ratio?
P/E ratio data for SYRE will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.
What is SYRE's market cap?
SYRE (Spyre Therapeutics Inc) has a market capitalization of $5.94 billion, making it a small-cap stock.
What is SYRE's price to book ratio?
SYRE trades at a price-to-book (P/B) ratio of 10.63, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.
Deep Dive Analysis
Explore comprehensive analysis tools to make an informed decision about Spyre Therapeutics Inc
Full Stock Analysis
Complete SYRE overview with charts and data
Is SYRE Undervalued?
DCF valuation and intrinsic value analysis
Dividend Analysis
Yield, payout ratio, and dividend history
Growth Analysis
Revenue, earnings, and expansion metrics
Financial Health
Debt, liquidity, and balance sheet strength
Price Prediction
2026 forecast and price targets
Stock Forecast
12-month price forecast and analyst targets
Earnings Date
Next earnings date and historical results
Compare Before You Buy
See how SYRE stacks up against its competitors
Similar Investment Decisions
Explore investment analyses for stocks similar to Spyre Therapeutics Inc
Complete SYRE Analysis
Compare SYRE With
Disclaimer
This analysis is for informational purposes only and should not be considered financial advice. The decision score and recommendations are based on quantitative factors and do not account for all risks, your personal financial situation, or qualitative factors. Always do your own research and consider consulting with a financial advisor before making investment decisions.